Kymera Investor Presentation Deck

KT-253 is a potent MDM2 degrader % MDM2 Remaining KT-253 is Superior to MDM2/p53 Small Molecule Inhibitors KT-253, unlike SMI's such as DS- 3032, strongly stabilizes p53... ... which leads to superior tumor cell killing (pM range) p53 MSD, 2h RS4;11, 24h CTG Company 300 250- 200 150 100 80 60 40 20 0 Clinical stage RS4-11 IC50 KT-253 DS-3032 Baseline 0.00001 0.0001 MDM2-HiBiT 0.001 0.01 Compound 1 Concentration, μM (nM) (AML Cell Killing) MDM2-HiBiT, DC50 (nM) (Degradation) DC50=0.4nM Ox 60 CD 40- 20 DMSO 3000- 2500- 0.3 0.4 2000 1500- 1000 KT-253 Kymera Phl 500- ¹0000¹0 KT-253 -DS-3032 0.0001 0.001 0.01 Concentration, μM DS-3032 Sankyo/Rain Ph II / combo AML 67 RG7388 Roche Ph II / III 220 100 80- -20 10000'0 KT-253 DS-3032 0.0001 SAR405838 Sanofi Paused 620 0.001 0.01 Concentration, μM HDM201 Novartis PhI/II 163 DMSO AMG-232 Amgen/Kartos Multiple Ph II 280 KT-253 is >200-fold more potent in tumor cell killing assays than SMIs due to its mechanism of action Proteomics show selective degradation of KT-253 KYMERA Ⓒ2023 KYMERA THERAPEUTICS, INC. PAGE 35

View entire presentation